Pharmaceutical Intellectual Property Rights and the Single Market

Více o knize

The thesis explores the challenges facing the European pharmaceutical sector, particularly in the context of an aging population and the industry's reliance on robust intellectual property rights. It highlights the financial pressures from expensive research and development, alongside threats from generic and counterfeit drugs. Additionally, it examines the economic implications of price disparities across EU member states, which facilitate the reimportation of pharmaceuticals, impacting producers' profits. The analysis includes insights from the European Court of Justice and the Court of First Instance.